MetaQon launches reproductive intelligence platform in India

In September 2026, MetaQon Precision Health announced the India rollout of MetaQon Reproductive Intelligence, a pre-cycle fertility workup designed to flag genetic and biological risk factors that standard first-line IVF testing may not identify.

India conducts an estimated 200,000 to 300,000 IVF cycles a year. IVF is not part of India’s public hospital system in general, while standard health insurance does not mandate fertility coverage. IRDAI requires insurers to disclose exclusions but does not mandate fertility coverage, leaving IVF, IUI, and ICSI as standard exclusions unless a couple has a specific rider. Such riders are uncommon and come with caps.

A single IVF cycle at a private clinic commonly costs ₹1.5 lakh to ₹3.5 lakh depending on the city. Most fertility specialists advise budgeting for two to three cycles before reassessing the approach. This can take a couple’s total expenditure beyond ₹5 lakh. Reported per-cycle success rates range from roughly 35 to 45 per cent for women under 35 to below 20 per cent after the age of 38.

According to MetaQon, the issue it is addressing is not a lack of testing, but the possibility that standard pre-cycle panels can appear normal while genetic or biological factors remain unidentified. These include inherited clotting disorders, methylation defects, and sperm DNA fragmentation.

MetaQon also said that the workup is intended to identify risks before a cycle rather than after a failed cycle. It cited thrombophilia and methylation variants as examples of factors that may remain unidentified despite a normal semen analysis and first-line hormone panel.

Impact on the Healthcare Market

MetaQon Reproductive Intelligence uses whole-genome data from both partners against reproductive genes and confirms flagged risks through a targeted blood biomarker panel. It also cross-checks the findings against a structured symptom review. The result is a ranked, clinic-ready order set for the couple’s doctor to act on.

According to MetaQon, the assessment is designed to help clinicians investigate factors such as inherited clotting predispositions, methylation-related genetic variants, and sperm DNA fragmentation, which may not be captured through conventional semen analysis or routine pre-cycle testing.

Impact on the Diagnostic Testing Market

The global diagnostic testing market size was calculated at USD 207.96 billion in 2025, grew to USD 213.03 billion in 2026, and is predicted to surpass USD 281.56 billion by 2035, poised to grow at a CAGR of 3.08% between 2026 and 2035.

According to Precedence Research, the market is anticipated to be driven by the rising popularity of decentralized health systems. Additionally, it is anticipated that the market will grow during the forecast period due to the adoption of new breakthroughs and technical improvements in the sector by major market players. In the upcoming years, growth in the point-of-care diagnostics market is anticipated as a result of these factors.

The benefits of digital health technologies include increased operational efficiency at health facilities, like hospitals, enhanced patient health outcomes through personalized treatment plans, decreased healthcare costs for both patients and providers, and expanded access to health care to historically marginalized communities. As a result, diagnostic tests have demonstrated value in the management of chronic illness conditions as well as in the prevention, identification, and diagnosis of disease. Clinical diagnostics open up new possibilities for early prevention and intervention by identifying individual risk factors and early warning indications. As a result, it is anticipated that the entire market would continue to grow as the frequency of chronic illnesses rises.